Besides, the PD-1.3 A-allele could disrupt the binding site for RUNX1 transcription factors, which causes the impairment of PD-1 inhibitory effect and higher lymphocyte activity, thus enhancing tumor immunity capacity and reducing the liability of cancer cells [29, 90]. The gene discussed is RUNX1; the disease is cancer.